Despite the underexpression of TGFβ signaling pathway inside the tumor, the systemic application of TGFβ blockade in patients before and after RCC surgery could also be justified—in order to disrupt the tumor-induced immunosuppression. Here, TGFB1 is linked to neoplasm.